Home
About
Share This
Set as HomepageSanofi
Sanofi Divests Dermik Dermatology Unit to Valeant ...
PRESS RELEASE 1/2 Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. - Strategic Divestiture to focus on Growth Platforms in the United States and Canada - Paris, France - July 11, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the strategic ...
Sanofi-aventis Press Release - (aflibercept) in Second-line ...
Sanofi-aventis Press Release Sanofi-aventis and Regeneron Report Positive Phase III Results with ZALTRAP ® (aflibercept) in Second-line Metastatic Colorectal Cancer
HIGHLIGHTS OF PRESCRIBING INFORMATION
sanofi-aventis Subject: Xyzal Prescribing Information Keywords: Xyzal (levocetirizine dihydochloride) Prescribing Information Created Date: 1/27/2011 12:11:04 PM
Sanofi-aventis to Acquire Genzyme
Sanofi-aventis Genzyme Media Contact : Media Contact : Jean-Marc Podvin Bo Piela +33 1 53 77 44 50 617-768-6579 508-308-9783 Investor Contact : Investor Contact : Sébastien Martel Patrick Flanigan +33 1 53 77 45 45 617-768-6563 617-816-9521 CONFERENCE CALL Sanofi-aventis and Genzyme will host ...
ARALEN CHLOROQUINE PHOSPHATE, USP - DESCRIPTION
ARALEN (chloroquine phosphate) Author: sanofi-aventis Subject: ARALEN PI Keywords: ARALEN chloroquine phosphate Created Date: 11/5/2008 4:41:29 PM
Calcimar (calcitonin salmon)
PRODUCT MONOGRAPH CALCIMAR® SOLUTION (Synthetic Calcitonin-Salmon) Calcium Regulator sanofi-aventis Canada Inc. Date of Revision: 2150 St. Elzear Blvd. West May 9, 2006 Laval, Quebec H7L 4A8 Submission Control No.: 105770 s-a Version 1.2 dated February 26, 2007
PRODUCT MONOGRAPH
PRODUCT MONOGRAPH Pr SUPRAX ® Cefixime tablets, Mfr. Std., 400 mg Cefixime for oral suspension, Mfr. Std., 100 mg/5 mL Antibiotic sanofi-aventis Canada Inc. 2150 St. Elzear Blvd. West Laval, Quebec H7L 4A8 Submission Control No. : 142028 Date of Revision: November 25, 2010 s-a Version 4.0 dated ...
General Conditions of Purchase of Sanofi-Aventis Deutschland GmbH
General Conditions of Purchase of Sanofi-Aventis Deutschland GmbH Status 27 August 2007 1. Application The following General Conditions of Purchase shall be an integral part of all purchase and supply contracts concluded by us with the Supplier.
COMPENSATION OF THE CHAIRMAN AND THE CEO
COMPENSATION OF THE CHAIRMAN AND THE CEO . In accordance with the recommendations of the AFEP-MEDEF corporate governance code, sanofi aventis is publishing below details of the compensation arrangements for its Chief Executive Officer
STILNOX
sanofi-aventis australia pty ltd 12-24 Talavera Road Macquarie Park NSW 2113 This leaflet was prepared in February 2008 Australian Register Number(s)
